- Home
- BOLD vs GSIW Comparison
BOLD vs GSIW Comparison
Compare BOLD & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- GSIW
- Stock Information
- Founded
- BOLD 2018
- GSIW 2016
- Country
- BOLD United States
- GSIW Hong Kong
- Employees
- BOLD N/A
- GSIW N/A
- Industry
- BOLD
- GSIW
- Sector
- BOLD
- GSIW
- Exchange
- BOLD Nasdaq
- GSIW Nasdaq
- Market Cap
- BOLD 30.3M
- GSIW 27.2M
- IPO Year
- BOLD 2024
- GSIW 2023
- Fundamental
- Price
- BOLD $1.05
- GSIW $1.46
- Analyst Decision
- BOLD Buy
- GSIW
- Analyst Count
- BOLD 3
- GSIW 0
- Target Price
- BOLD $4.00
- GSIW N/A
- AVG Volume (30 Days)
- BOLD 205.8K
- GSIW 915.9K
- Earning Date
- BOLD 08-11-2025
- GSIW 12-31-2024
- Dividend Yield
- BOLD N/A
- GSIW N/A
- EPS Growth
- BOLD N/A
- GSIW N/A
- EPS
- BOLD N/A
- GSIW N/A
- Revenue
- BOLD N/A
- GSIW $1,313,795.00
- Revenue This Year
- BOLD N/A
- GSIW N/A
- Revenue Next Year
- BOLD N/A
- GSIW N/A
- P/E Ratio
- BOLD N/A
- GSIW N/A
- Revenue Growth
- BOLD N/A
- GSIW N/A
- 52 Week Low
- BOLD $1.01
- GSIW $0.35
- 52 Week High
- BOLD $6.24
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- GSIW 77.10
- Support Level
- BOLD N/A
- GSIW $1.36
- Resistance Level
- BOLD N/A
- GSIW $1.78
- Average True Range (ATR)
- BOLD 0.00
- GSIW 0.17
- MACD
- BOLD 0.00
- GSIW 0.03
- Stochastic Oscillator
- BOLD 0.00
- GSIW 69.52
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.